Cambridge Healthtech Institute’s 2nd Annual
Advances in Purification Technologies
Delivering Higher Titer, Higher Throughput and Higher Purity Molecules
August 6-7, 2015
Part of CHI's 7th Annual The Bioprocessing Summit
August 3-7, 2015 | Westin Copley Place Hotel | Boston, Massachusetts
The downstream processing field is experiencing a resurgence of vitality and innovation. Driven partly by the quest for higher titer and higher throughput for existing mAb processes and partly by the next generation, non-monoclonal molecules coming down the pipeline, we are seeing exciting new developments in each step of downstream processing - from capture to purification to polishing. New, higher capacity and multi-modal ligands that can eliminate aggregates; advances in filters and flocculants for better binding and getting rid of impurities; process improvements from 3 column to 2 columns and the promise of continuous purification technologies - all these are testaments to the exciting innovations that aim to deliver higher purity, higher titer and higher throughput.
CHI’s Second Annual Advances in Purification Technologies will invite scientists and engineers to share their experiences, trials and results with these new technologies and continuing improvements, where they have encountered challenges, and what pitfalls to avoid.
Topics include, but are not limited to:
Chromatography, New Ligands and Chromatographic Media
- Moving from 3 columns to 2 columns
- Single-use downstream chromatography technology
- Pre-packed columns
- High capacity resins and ion exchange
- Multi-modal chromatography - Optimize
elimination of aggregates
- Stimuli responsive polymers
- Advances in filters – better filters to bind DNA
- Advances in membrane adsorbers for polishing
- High binding capacity membranes coupled with
high flow rate to remove residual HCP and DNA proteins
- Advances in flocculants – is it predictive of
larger scale purification?
- Modular viral clearance package
- Continuous processing – PCC, SMB, CCTC, MCC etc.
Purification of Complex/Next Generation Products – Bispecifics, Fab, Single-Domains, Membrane Proteins, ADCs, Vaccines etc.
- Is there a common platform for different formats?
- How to optimize production of ADCs
- Purification challenges for Bispecifics, fusion proteins, antibody fragments (Fab, scFv, Dab etc)?
- How to separate half-antibody from full-antibody, homodimers from heterodimers?
- Use of QbD and DOE in process design and purification of novel formats
High Throughput Purification
Screening and Automation
Scaled-down Processes as
Predictive Models for Large Scale Manufacturing
- Can you streamline smaller scale production and
make it effective?
- Is the DOE predictive of the larger scale
The deadline for submission is January 30, 2015. Click here to submit your proposal.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For more details on the conference,
Sr. Conference Director
Phone: (+1) 816-471-0701
For exhibit & sponsorship opportunities,
Manager, Business Development
For media partnership opportunities,
Director of Product Marketing